170 related articles for article (PubMed ID: 32291777)
21. Proteasome inhibitor associated thrombotic microangiopathy.
Yui JC; Van Keer J; Weiss BM; Waxman AJ; Palmer MB; D'Agati VD; Kastritis E; Dimopoulos MA; Vij R; Bansal D; Dingli D; Nasr SH; Leung N
Am J Hematol; 2016 Sep; 91(9):E348-52. PubMed ID: 27286661
[TBL] [Abstract][Full Text] [Related]
22. Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System.
Mina SA; Muhsen IN; Burns EA; Sarfraz H; Pingali SR; Xu J; Hashmi SK
Turk J Haematol; 2021 Aug; 38(3):218-221. PubMed ID: 34190655
[TBL] [Abstract][Full Text] [Related]
23. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
24. Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma.
Chan KL; Filshie R; Nandurkar H; Quach H
Leuk Lymphoma; 2015 Jul; 56(7):2185-6. PubMed ID: 25547654
[No Abstract] [Full Text] [Related]
25. Thrombotic microangiopathy after carfilzomib in a very young myeloma patient.
Jeyaraman P; Borah P; Singh A; Chhabra GD; Khullar D; Dayal N; Naithani R
Blood Cells Mol Dis; 2020 Mar; 81():102400. PubMed ID: 31887694
[No Abstract] [Full Text] [Related]
26. Ixazomib-induced thrombotic microangiopathy.
Yui JC; Dispenzieri A; Leung N
Am J Hematol; 2017 Apr; 92(4):E53-E55. PubMed ID: 28133842
[No Abstract] [Full Text] [Related]
27. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
[TBL] [Abstract][Full Text] [Related]
28. Update on proteasome inhibitors in multiple myeloma.
Richardson PG
Clin Adv Hematol Oncol; 2014 Mar; 12(3):179-81. PubMed ID: 24927266
[No Abstract] [Full Text] [Related]
29. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.
Gandhi PK; Gentry WM; Bottorff MB
Pharmacotherapy; 2012 Oct; 32(10):902-9. PubMed ID: 23033229
[TBL] [Abstract][Full Text] [Related]
30. Proteasome Inhibitor Drugs.
Fricker LD
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():457-476. PubMed ID: 31479618
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in proteasome inhibitor-based cancer therapies.
Dou QP
Curr Cancer Drug Targets; 2014; 14(6):505. PubMed ID: 25092106
[No Abstract] [Full Text] [Related]
32. [Development and clinical application of novel proteasome inhibitors].
Iida S
Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
[No Abstract] [Full Text] [Related]
33. Proteasome inhibitors.
Cvek B
Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
[TBL] [Abstract][Full Text] [Related]
34. Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review.
Terao T; Tsushima T; Miura D; Ikeda D; Fukumoto A; Kuzume A; Tabata R; Narita K; Takeuchi M; Matsue K
Leuk Lymphoma; 2022 May; 63(5):1102-1110. PubMed ID: 35373680
[TBL] [Abstract][Full Text] [Related]
35. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
36. Thrombotic microangiopathy during carfilzomib use: case series in Singapore.
Chen Y; Ooi M; Lim SF; Lin A; Lee J; Nagarajan C; Phipps C; Lee YS; Grigoropoulos NF; Lao Z; Surendran S; Teh EM; Goh YT; Chng WJ; Gopalakrishnan SK
Blood Cancer J; 2016 Jul; 6(7):e450. PubMed ID: 27471866
[No Abstract] [Full Text] [Related]
37. [Proteasome inhibitors].
Fuchida S; Shimazaki C
Nihon Rinsho; 2015 Feb; 73 Suppl 2():267-71. PubMed ID: 25831765
[No Abstract] [Full Text] [Related]
38. Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma.
Noonan K; Colson K
Semin Oncol Nurs; 2017 Aug; 33(3):279-291. PubMed ID: 28666621
[TBL] [Abstract][Full Text] [Related]
39. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
[TBL] [Abstract][Full Text] [Related]
40. Thrombotic microangiopathies and antineoplastic agents.
Grangé S; Coppo P;
Nephrol Ther; 2017 Apr; 13 Suppl 1():S109-S113. PubMed ID: 28577731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
